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Abstracts: Background: Although several studies have evaluated the change of cognitive per-
formance after severe carotid artery stenosis, the results still remain elusive. The objective of this 
study was to assess changes in cognitive function, depressive symptoms and Health Related Qual-
ity of Life (HRQoL) after carotid stenosis revascularisation and Best Medical Treatment (BMT). 
Methods: Study involved 213 patients with ≥70% carotid stenosis who underwent assessment of 
cognitive function using Montreal Cognitive Assessment scale (MoCA), depressive symptoms - 
using Patient Health Questionnaire-9 (PHQ-9) and HRQoL - using Medical Outcome Survey Short 
Form version 2 (SF-36v2). The assessment was performed before and at 6 and 12 months follow-
up periods in patients who had Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS) or 
received BMT only.  
Results: Improvement in the total MoCA scores was observed after 6 and 12 months (p<0.001, 
Kendall's W=0.28) in the CEA group. In the CAS group - after 12 months (p=0.01, Kendall's 
W=0.261) whereas in the BMT group - no significant changes (p=0.295, Kendall's W=0.081) were 
observed. Reduction of depressive symptoms was not found in any of the study groups. Comparing 
mean SF-36v2 scores in the CEA group, there was no significant difference in any of 10 subscales. 
Likewise in the CAS group - no significant difference in 9 of 10 subscales (p=0.028, η2=0.343) 
was observed. Three subscales worsened in the BMT group during the 1-year follow-up period.  
Conclusion: Patients with severe carotid stenosis who underwent revascularisation enhanced their 
cognitive performance without exerting significant change of depressive symptoms. Preoperative 
HRQoL may be maintained for at least one year in the CEA group. 
Keywords: Cognition, depression, quality of life, carotid stenosis, endarterectomy, stenting, medical treatment. 
1. INTRODUCTION 
Carotid artery stenosis is a well-known causal risk factor 
for ischaemic stroke. Approximately 10-15% of all strokes 
follow thromboembolism from previously asymptomatic 
>50% internal carotid artery stenosis [1]. In addition to func-
tional disability, stroke patients frequently go on to develop 
cognitive impairment and depression. The prevalence of 
post-stroke cognitive impairment ranges from 20% to 80% 
[2], whereas the prevalence of post-stroke depression has 
been reported as 31% at any time point within 5 years fol-
lowing stroke [3]. Therefore, not only functional disabilities 
but also post-stroke cognitive impairment and depression 
significantly affect Health Related Quality of Life (HRQoL). 
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However, there is less knowledge and evidence regarding 
neuropsychological symptoms in patients with severe as-
ymptomatic carotid stenosis. Several pathogenetic mecha-
nisms for the development of cognitive impairment such as 
microembolism, hypoperfusion and reduced cerebrovascular 
reserve [4, 5] have been proposed, but the definite effect of 
revascularisation on cognitive function in patients with se-
vere carotid stenosis is still unknown because the results of 
studies on the topic remain controversial [6]. However, the 
questions of whether carotid stenosis causes cognitive im-
pairment and whether carotid interventions improve cogni-
tive function have been discussed lately in clinical practice. 
For the first time, this topic has been mentioned in the guide-
lines of the European Society for Vascular Surgery [7] as 
well. While the results from controlled randomised CREST-
2 trial are awaited in years to come [8], the current study 
demonstrates not only the change in cognitive function, de-
pressive symptoms and HRQoL after revascularisation but 
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also the change in the Best Medical Treatment (BMT) group 
in patients with severe carotid stenosis. 
Advances in prevention and healthcare have increased 
life expectancy and produced a shift in the burden of dis-
eases worldwide. Therefore, besides cognitive impairment, 
vascular depression as a subtype of late-life depression is of 
great interest because of its clinical significance and complex 
basis, which may affect outcomes in the depressed elderly 
and increase the risk of cognitive impairment and poor qual-
ity of life [9]. Therefore, the goal of contemporary manage-
ment is not only to reduce stroke risk and to extend life ex-
pectancy but also to ensure a sufficiently high long-term 
HRQoL [10]. 
The aim of this study was to assess long-term changes in 
cognitive function, depressive symptoms and HRQoL after 
carotid stenosis revascularisation and BMT. We hypothe-
sised that patients with severe carotid stenosis would have 
improvement of cognitive function, depressive symptoms 
and HRQoL after revascularisation whereas the improve-
ment would not be seen in the BMT group. 
2. MATERIALS AND METHODS 
2.1. Participants and Study Design 
Between March 2015 and October 2017, 213 patients 
with severe carotid stenosis (≥ 70% luminal narrowing) were 
recruited from the Stroke Unit, Outpatient Stroke Clinic and 
Cardiology Department at Pauls Stradins Clinical University 
Hospital for this prospective observational study. The inclu-
sion criteria for all consenting patients were as follows: age 
18 years or older, severe extracranial carotid stenosis ≥70%, 
and an indication for carotid artery revascularisation. Carotid 
stenosis in all patients was estimated with computed tomogra-
phy angiography and defined according to the North American 
Symptomatic Carotid Artery Endarterectomy Trial (NASCET) 
criteria [11]. Carotid stenosis was considered symptomatic if a 
minor stroke (NIHSS <3, modified Rankin Scale (mRS) <2 
[12]), transient ischaemic attack (TIA) or amaurosis fugax had 
occurred within 6 months prior to inclusion [13]. Asympto-
matic carotid stenoses were defined as having no previous 
clinical ipsilateral minor stroke, TIA or amaurosis fugax 
within the last 6 months [14]. The exclusion criteria were 
major stroke (NIHSS ≥4, mRS 3-5), carotid stenosis <70%, 
progressive cerebral pathology (tumour, multiple sclerosis, 
trauma or a history of cerebral surgery, Alzheimer's disease, 
Parkinson's disease), patients with known antidepressant 
therapy and refusal to attend long term follow-up.  
Management of severe carotid stenosis was conducted 
independently of the study by the treating physician and pa-
tient based on patient preference and characteristics accord-
ing to American Heart Association guidelines [15]. Patients 
who refused to receive Carotid Endarterectomy (CEA) or 
Carotid Artery Stenting (CAS) were enrolled in the BMT 
group. Therefore, 3 cohorts were formed from the study 
sample: 1) patients who underwent CEA, 2) patients who 
underwent CAS, and 3) patients who received BMT only. 
All patients were assessed 1-3 days before revascularisa-
tion by a trained neurologist-baseline visit 1 (V1). For pa-
tients who refused to receive revascularisation of carotid 
stenosis, evaluation was performed 1 day before discharge 
from the hospital. All patients underwent clinical and cogni-
tive assessment, evaluation of depressive symptoms and 
HRQoL. All patients in this study received recommendations 
to use pharmacological treatment after discharge from hospital 
including antiplatelet agents, statins or other hypolipidaemic 
medications, antihypertensive treatment to attain blood pres-
sure <140/90mmHg, strict control of hyperglycaemia if dia-
betic, counselling for smoking cessation, weight control, and 
regular physical exercise according to guidelines [16].  
Patients were asked to come to the follow-up visits at 6 
(visit 2-V2) and 12 (visit 3-V3) months ± 14 days after re-
vascularisation of carotid stenosis or after inclusion time 
point for those who received BMT only. Six-months and 
one-year follow-up periods were chosen to gain insight into 
evolution of cognitive, depressive symptoms, HRQoL and 
long-term outcome of patients after carotid stenosis treat-
ment. In addition to assessment of clinical, neurological, 
cognitive, depressive symptoms, evaluation of extracranial 
carotid arteries was also performed by duplex ultrasound to 
assess the rate of restenosis at 6-months and 1-year follow-
up time periods by a single experienced neurosonographer. 
2.2. Clinical Assessment 
At the baseline visit (V1), basic demographic characteris-
tics (age, sex, education), anthropometric and lifestyle char-
acteristics (weight, height, smoking), data on comorbidities 
(history of stroke or TIA, Coronary Artery Disease (CAD), 
Arterial Hypertension (AH), chronic heart failure, Atrial 
Fibrillation (AF), Diabetes Mellitus (DM), Peripheral Artery 
Disease (PAD) and others), use of medications and neuro-
logical examination results were recorded on a standardised 
form during an interview. Participants were classified as 
smokers if they were current smokers or had quit smoking 
within 5 years before enrolment. History of TIA or minor 
stroke was collected from previous medical records. Regular 
use of medications was also recorded on a standardised form. 
After the examination of neurological status, patients were 
required to undergo a standardised cognitive assessment and 
to complete questionnaires, which assessed depressive symp-
toms and HRQoL in the presence of a single neurologist who 
was blinded to patient data. 
At V2 and V3, aside from vascular risk factors, new co-
morbidities, neurological status and medication compliance, 
cognitive function, depressive symptoms and HRQoL were 
also reassessed. 
Besides the change in cognitive function, depression and 
HRQoL, the primary (ischaemic or haemorrhagic stroke, 
Myocardial Infarction (MI) or death during the periproce-
dural period or within 30 days after the baseline visit) and 
the secondary (stroke, acute coronary syndrome or death due 
to different causes within a year, except for the first 30 days) 
outcomes also were evaluated. 
2.3. Cognitive Assessment 
The cognitive assessment was performed using the Lat-
vian or Russian version of Montreal Cognitive Assessment 
Scale (MoCA), according to the patient's native language 
and instructions given by the authors [17]. The MoCA test 
was chosen because it has been approved as a valid 10-
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minute cognitive screening tool for vascular cognitive im-
pairment [18-21]. The MoCA test is divided into 7 subscores 
that assess 7 cognitive domains: visuospatial/executive, nam-
ing, attention, language, abstraction, memory, orientation 
and an additional point that is given to each patient who has 
an educational experience of 12 years or less. The MoCA 
scores range from 0-30, and a final total score of 26 and 
above is considered normal [18].  
2.4. Assessment of Depressive Symptoms 
Assessment of depressive symptoms was performed us-
ing the Patient Health Questionnaire-9 (PHQ-9), which has 
been compared with other questionnaires that screen depres-
sive symptoms. PHQ-9 is proposed to be an acceptable tool 
[22-24]. Moreover, the PHQ-9 has been used in vascular 
depression [25] and post-stroke depression [26, 27] studies. 
The PHQ-9 is a self-reporting 9-item questionnaire, and its 
scores range from 0 to 27 because each of the 9 questions 
can be scored from 0 (“not at all”) to 3 (“nearly every day”). 
A PHQ-9 score of 10 or greater is recommended as a screen-
ing cut point, because it has sensitivity for major depression 
of 88% a specificity of 88% [28]. Therefore, patients were 
categorised into two groups according to PHQ-9 score. 
PHQ-9 scores lower than 10 denoted no relevant depressive 
symptoms. Scores of 10 or higher indicated relevant depres-
sive symptoms. In this study validated Latvian and Russian 
versions of the PHQ-9 depression scale [29] were used.  
2.5. Assessment of Health Related Quality of Life 
HRQoL was measured using the Medical Outcome Sur-
vey Short Form 36 version 2 (SF-36v2) in Latvian and Rus-
sian languages [30]. The SF-36v2 includes 36 items that are 
grouped into eight subscales: Physical Functioning (PF); role 
limitations due to physical problems or Role-Physical (RP); 
Bodily Pain (BP); General Health (GH); Vitality (VT); So-
cial Functioning (SF); role limitations due to emotional prob-
lems or Role-Emotional (RE); and Mental Health (MH). In 
addition, the SF-36v2 provides summary scales for overall 
physical and mental health: Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores. For 
each item, scores are coded, summed and transformed into a 
scale from 0 (worst possible health state measured by the 
questionnaire) to 100 (best possible health state). A differ-
ence of 5 to 10 points is considered a clinically important 
change for an individual subject (a smaller difference may be 
important for group comparisons) [31].  
2.6. Treatment type of Carotid Stenosis 
All CEA procedures were performed by experienced 
board-certified vascular surgeons. Decision on which tech-
nique of plaque removal (regular endarterectomy or eversion 
endarterectomy) and administration of shunting during op-
eration was taken independently of the study by the treating 
surgeon. All CEA procedures were performed under general 
anaesthesia. 
All patients who underwent CAS were given acetylsali-
cylic acid (100 mg/day) and clopidogrel (75 mg/day) at least 
5 days prior the intervention or a loading dose (300 mg) 4 to 
5 hours prior to the procedure. CAS was performed under 
local anaesthesia. Distal protection devices and self-
expanding stents were used in all CAS procedures. After 
CAS all patients were recommended a lifelong application of 
100 mg acetylsalicylic acid and 75 mg clopidogrel for a 
minimum of 3 months after CAS, as well as vascular risk 
factor modification according to guidelines [16]. 
In the BMT group as well as in the CEA and CAS 
groups, in addition to antiplatelet agents, statins or other hy-
polipidaemic medications, antihypertensive treatment, strict 
control of hyperglycaemia if diabetic, counselling for smok-
ing cessation, weight control, and regular physical exercises 
were recommended [16]. 
2.7. Statistical Analysis 
Descriptive statistics were used to analyse the demo-
graphics and clinical characteristics of the population. Con-
tinuous variables were described as the median and Inter-
quartile Range (IQR) or as the means (Standard Deviation 
(SD)). As majority of the variables were not normally dis-
tributed and there was imbalance between groups, non-
parametric statistics were mainly used to evaluate variables. 
We used the Pearson's Chi-squared test to compare baseline 
categoric variables between the groups. For detection of dif-
ferences among three treatment groups (CEA, CAS, BMT), 
the Kruskal-Wallis test was applied. Changes in continuous 
variables at V1, V2 and V3 in each treatment group were 
calculated using the Friedman's test followed by the least 
significant difference post hoc test using the Wilcoxon 
signed rank test for paired continuous data and the McNemar 
test for paired categorical data. To understand whether dif-
ferences were statistically meaningful, we calculated 
Cramer's V for the Pearson's Chi-squared test, partial eta 
squared (η2) for Kruskal-Wallis and ANOVA (analysis of 
variance) tests; Kendall's coefficient of concordance (Ken-
dall's W) for Friedman's test, coefficient r for Wilcoxon 
signed rank test. Raw scores of cognitive, depression and 
HRQoL tests were used for the analysis. In the study of 
HRQoL, the results were expressed as the means ± SD ac-
cording to suggestions by Shan et al. [32]. Therefore, one-
way ANOVA was used for comparison of SF-36v2 mean 
scores between treatment groups and repeated measures 
ANOVA for comparing changes at follow-up visits in each 
group. A two-sided p-value <0.05 was considered statisti-
cally significant. Statistical analyses were performed using 
IBM SPSS Statistics (version 23 for Windows, IBM Corp., 
Somers, NY, USA). 
3. RESULTS 
3.1. Characteristics of Patients 
Initially 213 patients were recruited in the 3 following 
groups: patients who underwent CEA (n=159), patients who 
underwent CAS (n=29) and patients who received BMT only 
(n=25).  
There was no statistically significant difference by gen-
der - in each treatment group men were more common than 
women (p=0.226, Cramer's V=0.118). There were 95 (60%) 
men in the CEA group, 20 (69%) in the CAS group and 19 
(76%) in the BMT group. The median age in all three groups 
was similar: in the CEA group-71 (IQR: 63-75); in the CAS 
group-71 (IQR: 63.4-78) and in the BMT group -74 (IQR: 
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67-78) years (p=0.171, effect size η2=0.01). Comparing age 
differences between men and women in each group, we ob-
served a statistically significant difference only in the CEA 
group where women were older than men (p<0.001, η2=0.1)  
(Fig. 1). 
The difference between treatment groups regarding clini-
cal and neurological characteristics, cardiovascular risk fac-
tors was not statistically significant, except for CAD and 
chronic heart failure, AF and DM. Atrial fibrillation was 
more common in the BMT group (p=0.001, Cramer's 
V=0.255), but DM - in the CAS group (p<0.001, Cramer's 
V=0.281). Although CAD and chronic heart failure were 
more common in the CAS group (p=0.048 and p=0.034), the 
statistical effect size of the differences was small. The 
demographic, lifestyle and clinical characteristics of the pa-
tients in each group are presented in Table 1. 
During the one-year follow up period, primary and sec-
ondary outcomes were observed in 14 patients. The causes of 
primary outcome in the CEA group were perioperative dis-
abling stroke (n=2), large perioperative MI (n=1), and pe-
rioperative intracerebral haemorrhage (ICH) (n=1); in the 
CAS group, periprocedural infection with sepsis and death 
(n=1); but in the BMT group, there were no primary out-
come events during the first 30 days after the initiation of the 
study. The causes for secondary outcome in the CEA group 
were death (n=3) and contralateral disabling stroke  (n=2); in 
the CAS group death (n=2) was due to traumatic ICH and 
acute CAD but in the BMT group one patient had ipsilateral 
disabling stroke and one patient had acute CAD. The data of 
all these patients were analysed until the time point when the 
patient was unable to continue the study. However, there 
were some patients who did not want to continue to partici-
pate in the study during the follow-up period due to social 
background. In telephone interviews (at V2 or V3), no vas-
cular event or death was reported for subjects who inter-
rupted the study. Therefore, in the CEA group at the begin-
ning, there were 159 patients; after 6 months - only 132 pa-
tients continued to participate in the study, but after 12 
months, there were 128 patients. In the CAS group at the 
beginning, there were 29 patients; after 6 months, there were 
only 27 patients, but after 12 months, there were 25 patients. 
In the BMT group at the beginning, there were 25 patients; 
after 6 months - 24, but after 12 months, only 22 patients 
continued the study. 
3.2. Characteristics of Cognitive Function 
During cognitive assessment at the beginning of the 
study, there was no significant difference of median total 
MoCA scores as well as of median MoCA subtest scores 
between all treatment groups (p=0.728, η2=0.003). The me-
dian total MoCA score in the CEA group was 25 (IQR: 22-
27), in the CAS group - 24 (IQR: 21-26) and in the BMT 
group - 25 (IQR: 22-26). 
In the CEA group patients performed significantly better 
on the total MoCA scores after 6 and 12 months (p<0.001, 
Kendall's W=0.28). There was a statistically significant dif-
ference in median total MoCA scores between V1 and V2, as 
well as between V1 and V3. Although the difference in me-
dian total MoCA scores between V2 and V3 was statistically 
significant (p=0.001), the statistical effect size was small 
(r=0.2) (Fig. 2).  
Comparing median MoCA subtest scores during the fol-
low-up period, there was statistically significant improve-
ment in attention (p=0.035, Kendall's W=0.033), language 
(p<0.001,  Kendall's  W=0.075),  abstraction  (p<0.001, Ken  
 
Fig. (1). Age differences in the carotid endarterectomy, carotid stenting and best medical treatment groups at baseline. Comparison of me-
dian age in males and females at baseline. Significant differences between male and female median age were in the CEA group where fe-
males were older than males. No significant age differences were observed in the CAS and BMT groups at baseline. Bar display median, 
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p-value	   Effect Size	  
Neurological Characteristics	  
Asymptomatic, n (%)	   118 (74.2%)	   20 (69%)	   13 (52%)	  
Symptomatic	   -	   -	   -	  
Stroke, (NIHSS<3)	   22 (13.8%)	   6 (20.7%)	   10 (40%)	  
TIA	   16 (10.1%)	   2 (6.9%)	   1 (4%)	  
Amaurosis fugax	   3 (1.9%)	   1 (3.4%)	   1 (4%)	  
0.072	   Cramer's V 0.165	  
Stenosis Side, n (%)	  
Right	   66 (41.5%)	   12 (41.4%)	   8 (32.0%)	  
Left	   52 (32.7%)	   8 (27.6%)	   10 (40.0%)	  
Bilateral	   41 (25.8%)	   9 (31.0%)	   7 (28%)	  
0.845	   Cramer's V 0.057	  
Cardiovascular Risk Factors	  
Coronary artery disease	   68 (42.8%)	   19 (65.5%)	   9 (36.0%)	   0.048*	   Cramer's V 0.169	  
Chronic heart failure	   -­‐	   -­‐	   -­‐	  
Class II	   30 (18.9%)	   9 (31%)	   10 (40%)	  
Class III	   10 (6.3%)	   4 (13.8%)	   2 (8%)	  
Class IV	   0	   1 (3.4%)	   0	  
0.034*	   Cramer's V 0.197	  
Hypertension	  
Stage 2	   102 (64.2%)	   17 (58.6%)	   16 (64%)	  
Stage 3	   25 (15.7%)	   5 (17.2%)	   5 (20%)	  
0.709	   Cramer's V 0.094	  
Atrial fibrillation	   15 (9.4%)	   6 (20.7%)	   9 (36%)	   0.001*	   Cramer's V 0.255†	  
Peripheral artery disease	   49 (30.8%)	   11 (39.3%)	   5 (20%)	   0.314	   Cramer's V 0.105	  
Diabetes mellitus	   21 (13.2%)	   13 (44.8%)	   4 (16%)	   <0.001*	   Cramer's V 0.281†	  
Smoking	  
Non - smoker	   54 (34%)	   9 (44%)	   11 (44%)	  
Current smoker	   72 (45.3%)	   12 (41.4%)	   10 (40%)	  
Former smoker	   33 (20.7%)	   8 (27.6%)	   4 (16%)	  
0.764	   Cramer's V 0.066	  
BMI (mean, SD)	   27.12 (4.26)	   27.67 (4.27)	   27.29 (3.59)	   0.805	   η2=0.002	  
<18.4	   1 (0.6%)	   0	   0	  
18.5-24.9	   48 (30.2%)	   8 (27.6%)	   4 (16%)	  
25.0-29.9	   74 (46.5%)	   13 (44.8%)	   14 (56%)	  
≥30	   36 (22.6%)	   8 (27.6%)	   7 (28%)	  
0.835	   Cramer's V 0.081	  
Abbreviations: CEA - carotid endarterectomy group; CAS - carotid artery stenting group; BMT - best medical treatment group; NIHSS - National Institute of Health Stroke Scale; 
TIA- transient ischaemic attack; BMI - body mass index; SD - standard deviation. 
* p<0,05; † effect size Cramer's V=0,3 (medium). 
 
dall's W=0.076) and delayed recall (p<0.001, Kendall's 
W=0.217) subtest scores; however, the statistical effect size 
was small. There was no decline in any of the MoCA subtest 
scores (Table 2). 
Patients in the CAS group also improved in total MoCA 
scores during 1-year follow-up (p=0.01, Kendall's 
W=0.261). The difference between median total MoCA 
scores was statistically significant only between V1 and V3 
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(p=0.034, r=0.44). The median total MoCA scores before 
CAS, 6 and 12 months after CAS are presented in Fig. (3).  
Comparing median MoCA subtest scores during the fol-
low-up period, there was statistically significant improvement 
only in visuospatial/executive (p=0.01) subtest scores, but the 
statistical effect size was small (Kendall's W=0.24) (Table 3). 
Patients in the BMT group did not show statistically sig-
nificant changes in total MoCA scores in a 1-year period 
(p=0.295, Kendall's W=0.081): at the beginning of the study, 
the total MoCA score was 25 (IQR: 22-26), after 6 months - 
26 (IQR: 23-27) and after 12 months - 26 (IQR: 23-28). 
Comparing median MoCA subtest scores during the follow-
up period, we found statistically significant improvement 
specifically in memory (p=0.027) subtest scores, but the sta-
tistical effect size was small (Kendall's W=0.242) (Table 4). 
3.3. Characteristics of Depressive Symptoms 
At the beginning of the study, the median PHQ-9 scores 
were similar in all groups: in the CEA group: 5 (IQR: 2-9), 
in the CAS group: 6 (IQR: 2-10) and in the BMT group: 6 
(IQR: 3-10); p=0.3, η2=0.0142.  
In the CEA group, the median PHQ-9 scores did not 
change during the follow-up period (p=0.543, Kendall's 
W=0.008). Likewise, there was no statistically significant 
difference between the frequencies of depressive symptoms 
(PHQ-9 screening cut point ≥ 10) before and 6 or 12 months 
Fig. (2). Median total MoCA scores at baseline, 6 and 12 months in carotid endarterectomy group. Significant increase of median total 
MoCA score as a measure of cognitive function at 6 and 12 months after successful CEA in patients with severe carotid stenosis. The differ-
ence of median MoCA scores between V2 and V3 is statistically significant, but the statistical effect size is small (r=0.2). 
Bar display median, boxes represent IQR, and whiskers display total range.  
 
Table 2. Median MoCA subtest scores at baseline, after 6 and 12 months in the carotid endarterectomy group. 
- V1 V2 V3 p-value Effect Size 
Total MoCA  25 (22-27) 26 (24-28) 27 (25-29) <0.001* 0.28† 
VSE 4 (3-5) 4 (3-5) 4 (4-5) 0.254 0.013 
Naming 3 (3-3) 3 (3-3) 3 (3-3) 0.135 0.019 
Attention 5 (6-6) 5 (6-6) 5 (6-6) 0.035* 0.033 
Language 2 (1-2) 2 (1-2) 2 (1-3) <0.001* 0.075 
Abstraction 2 (1-2) 2 (1-2) 2 (2-2) <0.001* 0.076 
Delayed recall 3 (1-4) 4 (2-5) 4 (3-5) <0.001* 0.217 
Orientation  6 (6-6) 6 (6-6) 6 (6-6) 0.103 0.023 
Abbreviations: CEA - carotid endarterectomy; V1 - baseline visit before endarterectomy, V2 - visit 2 (6 months after endarterectomy), V3- visit 3 (12 months after endarterectomy); 
VSE - visuospatial/executive functions. 
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after CEA (p=0.485, Kendall's W=0.007). In our analysis, 
from those patients who had depressive symptoms before 
CEA, more than half of them did not feel depressed after 6 
months (n=18; 58.1%) as well as after 12 months (n=16 
(59.2%)). However, the differences between patients who 
remained depressed and those whose symptoms did get bet-
ter at 6 (p=0.17) and 12 months (p=0.557) were not statisti-
cally significant. The changes in the frequency of depressive 
symptoms after 6 and 12 months in the CEA group are pre-
sented in Fig. (4).  
In the CAS group, median PHQ-9 scores did not change 
(p=0.17, Kendall's W=0.093). There was no statistically sig-
nificant difference between the frequencies of depressive 
symptoms before and 6 or 12 months after CAS (p=0.165, 
Kendall's W=0.095). In the analysis of depressive symptoms 
after 6 months, only one from 8 patients who had depressive 
symptoms before CAS did get better. Likewise, 12 months 
after CAS, depressive symptoms were not observed in 3 
from 8 patients. The differences between patients who re-
mained depressed and those whose symptoms did get better 
at 6 (p=0.375) and 12 months (p=0.97) were not statistically 
significant. The changes in the frequency of depressive 
symptoms after 6 and 12 months in the CAS group are pre-
sented in Fig. (5). 
In the BMT group median PHQ-9 scores did not change 
during the follow-up period compared with baseline 
Fig. (3). Median total MoCA scores at baseline, 6 and 12 months in carotid artery stenting group. Significant increase of median total MoCA 
score as a measure of cognitive function at 12 months after successful CAS in patients with severe carotid stenosis. No significant change of 
median MoCA score was observed between baseline and 6 months and between 6 and 12 months. Bar display median, boxes represent IQR, 
and whiskers display total range.  
	  
Table 3. Median MoCA subtest scores at baseline, after 6 and 12 months in the carotid artery stenting group. 
- V1 V2 V3 p-value Effect size 
Total MoCA 24 (21-26) 24.5 (21-28) 25 (22-28) 0.01* 0.261† 
VSE 3 (2-5) 4 (3-5) 4 (3-5) 0.01* 0.24 
Naming 3 (3-3) 3 (3-3) 3 (3-3) 0.368 0.053 
Attention 5 (4-6) 6 (5-6) 5 (4-6) 0.572 0.029 
Language 2 (1-2) 1 (1-2) 1 (1-2) 0.917 0.005 
Abstraction 2 (1-2) 1 (1-2) 2 (1-2) 0.289 0.065 
Delayed recall 3 (0.75-4) 4 (1.75-4) 3 (1.75-4) 0.144 0.108 
Orientation  6 (6-6) 6 (6-6) 6 (6-6) 0.368 0.053 
Abbreviations: CAS - carotid artery stenting; V1 - baseline visit before carotid stenting, V2 - visit 2 (6 months after carotid stenting), V3- visit 3 (12 months after carotid stenting); 
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(p=0.64, Kendall's W=0.03). In addition, in the analysis of 
the frequencies of depressive symptoms, there was no statis-
tically significant difference between baseline and 6 or 12 
months after initiation of BMT (p=0.819, Kendall's 
W=0.013). In the analysis, from those who had depressive 
symptoms at baseline, only two out of 6 patients were free 
from depressive symptoms after 6 months and 2 out of 7 
after 12 months. The differences between patients who re-
mained depressed and those whose symptoms did get better 
at 6 (p=0.687) and 12 months (p=0.243) were not statisti-
cally significant. The changes in the frequency of depressive 
symptoms after 6 and 12 months in the BMT group are pre-
sented in Fig. (6). 
3.4. Characteristics of Health Related Quality of Life 
At baseline, SF-36v2 subscale scores were similar in all 
three study groups. The lowest mean scores in all groups 
were for GH, PCS and MCS, and the highest were for SF in 
the CEA and BMT groups. Although mean SF-36v2 scores 
for PF and BP were significantly lower in the CAS group 
than in CEA and BMT groups (p<0.05), the statistical effect 
size was small (Table 5).  
Comparing mean SF-36v2 scores in CEA group during 
the follow-up period, there was no statistically significant 
difference in any of 10 subscales. The lowest mean SF-36v2 
scores for GH, PCS and MCS and the highest mean SF-36v2 
scores for SF remained unchanged after 6 and 12 months. 
Likewise, comparing mean SF-36v2 scores in CAS group, 
there was no statistically significant difference in 9 of 10 
subscales during the follow-up period, except for BP 
(p=0.028, η2=0.343). Before revascularisation, the mean BP 
score was 48.4 (27.2), after 6 months - 54.3 (30) and after 12 
months - 45.2 (17.8). The lowest mean SF-36v2 scores for 
RP, GH, VT, PCS and MCS remained unchanged after 6 and 
12 months. For PF and SF there were decrements in the 
mean SF-36v2 scores after 12 months, but the changes were 
not statistically significant. Nevertheless, in the BMT group 
there were statistically significant differences in RP  
mean scores during the follow-up period (p=0.039, η2=0.392)  
Table 4. Median MoCA subtest scores at baseline, after 6 and 12 months in the best medical treatment group. 
- V1 V2 V3 p-value Effect Size 
Total MoCA 25 (22-26) 26 (23-27) 26 (23-28) 0.295 0.081 
VSE 4 (3-4) 4 (3-5) 4 (2-5) 0.973 0.002 
Naming 3 (3-3) 3 (3-3) 3 (3-3) 1.0 <0.001 
Attention 6 (6-6) 6 (5-6) 6 (5-6) 0.507 0.045 
Language 2 (1-2) 1 (1-2) 2 (1-3) 0.531 0.042 
Abstraction 2 (1-2) 2 (2-2) 2 (2-2) 0.229 0.098 
Delayed recall 2 (2-3) 3 (2-4) 4 (3-5) 0.027* 0.242 
Orientation  6 (6-6) 6 (6-6) 6 (6-6) 0.999 >0.099 
Abbreviations: BMT - best medical treatment group; V1 - baseline visit, recruitment in the study, V2 - visit 2 (6 months after recruitment), V3- visit 3 (12 months after recruitment); 
VSE - visuospatial/executive functions; Median values (IQR:Q1- Q3); * p<0.05. 
 
Fig. (4). Changes in the frequency of depressive symptoms after 6 and 12 months in the carotid endarterectomy group. (A) Graph of percent-
age and number of patients with and without depressive symptoms at baseline and 6 months after CEA. The graph depicts number of patients 
who did not have depressive symptoms at baseline but felt depressed after 6 months. Likewise, number of patients who had depressive symp-
toms at baseline but did get better or remained depressed after 6 months. (B) Graph of percentage and number of patients with and without 
depressive symptoms at baseline and 12 months after CEA. The graph depicts number of patients who did not have depressive symptoms at 
baseline but felt depressed after 12 months. Likewise, number of patients who had depressive symptoms at baseline but did get better or re-
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Fig. (5). Changes in the frequency of depressive symptoms after 6 and 12 months in the carotid artery stenting group. (A) Graph of percent-
age and number of patients with and without depressive symptoms at baseline and 6 months after CAS. The graph depicts number of patients 
who did not have depressive symptoms at baseline but felt depressed after 6 months. Likewise, number of patients who had depressive symp-
toms at baseline but did get better or remained depressed after 6 months. (B) Graph of percentage and number of patients with and without 
depressive symptoms at baseline and 12 months after CAS. The graph depicts number of patients who did not have depressive symptoms at 
baseline but felt depressed after 12 months. Likewise, number of patients who had depressive symptoms at baseline but did get better or re-
mained depressed after 12 months. 
 
Fig. (6). Changes in the frequency of depressive symptoms after 6 and 12 months in the best medical treatment group. (A) Graph of percent-
age and number of patients with and without depressive symptoms at baseline and 6 months after BMT. The graph depicts number of patients 
who did not have depressive symptoms at baseline but felt depressed after 6 months. Likewise, number of patients who had depressive symp-
toms at baseline but did get better or remained depressed after 6 months. (B) Graph of percentage and number of patients with and without 
depressive symptoms at baseline and 12 months after BMT. The graph depicts number of patients who did not have depressive symptoms at 
baseline but felt depressed after 12 months. Likewise, number of patients who had depressive symptoms at baseline but did get better or re-
mained depressed after 12 months. 







(n=25)	   p- value	  
Effect Size	  
η2	  
Physical Functioning (PF)	   66.6 (22.4)	   53.4 (23)	   57 (30)	   0.036*	   0.031	  
Role-Physical (RP)	   55.4 (26.7)	   47.7 (25.7)	   57.1 (27.4)	   0.158	   0.017	  
Bodily Pain (BP)	   60 (27)	   48.4 (27.2)	   66.7 (26.4)	   0.009*	   0.044	  
General Health (GH)	   47.6 (17)	   44.7 (19.5)	   47.5 (25.6)	   0.297	   0.015	  
Vitality (VT)	   56.7 (18.6)	   49.7 (20.7)	   60.4 (20.1)	   0.173	   0.017	  
Social Functioning (SF)	   71.7 (25.3)	   65.1 (27.2)	   75.8 (19.2)	   0.671	   0.004	  
Role-Emotional (RE)	   65 (27.7)	   57.9 (27.3)	   71.7 (23.1)	   0.231	   0.014	  
Mental Health (MH)	   63.5 (17.5)	   62.6 (21.7)	   71.3 (15)	   0.238	   0.014	  
Physical Component Summary (PCS)	   44 (8.5)	   39.7 (8.3)	   42.1 (8.9)	   0.09	   0.023	  
Mental Component Summary (MCS)	   45.5 (10.1)	   44.5 (10.9)	   50.1 (7.8)	   0.285	   0.012	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where at the beginning of the study mean RP score was 57.1 
(27.4), but after 6 months - 34.6 (20.4) and after 12 months 
37.5 (24.4). Likewise, mean SF-36v2 scores for bodily pain 
were significantly different during follow-up periods 
(p=0.051, η2=0.368): at the beginning of the study, the mean 
BP score was 66.7 (26.4), but after 6 months it was 57.3 
(25.1) and after 12 months - 64.5 (24.3). There were statisti-
cally significant changes in MCS mean scores during the 
follow-up period as well: at the baseline, the mean MCS 
score was 50.1 (7.8), but after 6 months, it was 47.9 (7.3) 
and after 12 months - 44.5 (7.8). The lowest mean scores for 
GH, PCS, MCS and the highest scores for SF in the BMT 
group remained unchanged during the follow-up periods. 
The results of the mean SF-36v2 scores during the follow-up 
periods are summarised in Fig. (7). 
Compared with CAS and BMT group, CEA group pa-
tients had better scores at 6 months for 3 of the 10 SF-36v2 
subscales: for PF (p=0.001, η2=0.076), RP (p=0.012, 
η2=0.05) and for PCS (p=0.005, η2=0.061). By 12 months of 
follow-up, although 7 of the 10 subscales (PF, RP, VT, SF, 
RE, MH and MCS) had better scores in the CEA group 
(p<0.05), the effect size of statistical significance was me-
dium only for PF (p=0.004, η2=0.065) and SF (p=0.002, 
η2=0.072) domains.  
4. DISCUSSION 
Although older studies do not show changes in cognitive 
function after CEA or CAS [33], the current study indicates 
significant improvement of cognitive function after revascu-
larisation of severe carotid stenosis, except in the BMT 
group, where the observed improvement was not statistically 
significant. The significant improvement in revascularisation 
groups could be explained by "mechanical" improvement of 
blood flow and subsequent restoration of cerebral perfusion 
after CEA or CAS in addition to BMT. As cognitive decline 
was not observed in the BMT group, it may indicate that 
there could be benefits not only from "mechanical" revascu-
larisation of carotid stenosis by removal of atherosclerotic 
plaque, but also from BMT regarding cognitive function 
because BMT alters the pathogenetic mechanisms of cerebral 
small vessel disease. Reducing atherosclerotic load in cere-
bral small vessels, which is a cause for white matter burden 
[34], it could positively affect cognitive performance. There-
fore, combined medical and surgical or endovascular inter-
ventions may halt or reverse cognitive impairment. 
On the other hand, the probability of a practice or learn-
ing effect of the MoCA test may also be one of the causes or 
explanations for the improvement of cognitive performance. 
To minimise the practice effect, we chose follow-up time 6 
and 12 months. Although Plessers et al. have shown a prac-
tice effect of repeated neurocognitive testing [35], these re-
sults remain equivocal. In their research cognitive impair-
ment was observed at baseline in the study group as well as 
in the control group. The control group consisted of patients 
with PAD who shared the same cardiovascular risk factors as 
the patients with severe carotid stenosis. The results are in-
conclusive because it is unknown whether the improvement 
of cognitive function in the study and control groups could 
be explained only by the practice effect or by fact that there 
was a comprehensive management of cardiovascular risk 
factors in both study groups, which reduces the risk of cogni-
tive decline itself [36] or by both practice and management 
of cardiovascular risk factors. 
In the analysis of MoCA subtest scores during the fol-
low-up period, slight discrepancy between treatment groups 
was detected. In the CEA group MoCA subtest analysis 
showed significant improvement in multiple domains as at-
tention, language, abstraction and delayed recall (p<0.04); in 
the CAS group, improvement was observed only in a visu-
ospatial/executive subtest (p=0.01); in the BMT group - in a 
delayed-recall subtest (p=0.027). However, the effect size 
was small for all statistically significant improvements. The 
disparity of improvement in various domains could be ex-
plained by partial overlap of some subtests for assessment of 
main cognitive domains in the MoCA scale. For example, 
the two-item abstraction and phonemic fluency tasks are part 
of executive function assessment as well [18]. Therefore, we 
may state that in addition to attention, language and memory, 
executive function may also be partly improved in the CEA 
group. Likewise, the findings of MoCA subtests in the CEA 
group could be congruent with the improvement of MoCA 
subtests after CAS and in the BMT group. On the other 
hand, the statistical effect size was small in each group, thus 
these findings could change if the study populations were 
larger. In addition, MoCA as a screening tool is not as sensi-
tive as comprehensive sophisticated standardised neuropsy-
chological cognitive assessment tests, which could reveal 
subtler changes in cognitive domains compared with a 
screening tool.  
In the literature, there are only few studies that have 
evaluated and compared long-term changes in cognitive 
function after carotid stenosis revascularisation (CEA, CAS) 
and BMT. Although methodological differences make mean-
ingful comparison of results across studies challenging, main 
conclusions of these findings are similar. In the studies 
where cognitive function was assessed, improvement of total 
MoCA score in a year after revascularisation (CEA, CAS), 
but not in the BMT group was observed. Furthermore, the 
CEA group showed improvement in executive and memory 
MoCA subtest scores, which is partially congruent with our 
findings [37]. The improvement of these domains is consis-
tent with results that show association between reduced per-
fusion of anterior circulation and worse executive and mem-
ory function [38]. Furthermore, the revascularisation and 
improvement of blood flow in the middle cerebral artery is 
associated with greater improvement in attention and execu-
tive function [39]. In the studies where changes in cognitive 
function in a year after CEA or CAS versus the control 
group was assessed with the MoCA test, the results indicated 
that cognitive function might improve or at least do not de-
cline in symptomatic and asymptomatic elderly patients with 
severe carotid stenosis who had revascularisation [40, 41]. 
Comparing studies where long-term effects of different ca-
rotid stenosis treatment methods (CEA, CAS or BMT) on 
cognitive function were assessed, their results also show that 
revascularisation of carotid stenosis improves long-term 
cognitive performance, independent of treatment type [42-
46]. Except, older studies have suggested that there is no 
difference between cognitive function before and after  
carotid stenosis revascularisation (CEA, CAS) [47, 48]. How- 
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Fig. (7). Results of mean SF-36v2 scores during the follow-up period in all study groups. Trend in SF-36v2 scores from baseline to 1 year. 
Higher scores indicate better quality of life. Significant differences (p<0.05) in scores were not observed in the CEA group during 1 year 
follow up period. In the CAS group SF-36v2 scores did not change during the follow up period except for bodily pain (p=0.02) where worst 
scores were after 12 months. In the BMT significant differences in scores were noted in 3 of 10 subscales (role physical, bodily pain and men-
tal component summary). Compared with CAS and BMT group, CEA group patients had better scores at 6 months for 3 of the 10 SF-36v2 
subscales (physical functioning, role physical and physical component summary). Plotted values at each timepoint represent means and stan-
dard deviation derived from the analysis of covariance. CEA = blue, CAS = red, BMT = grey. 
ever, comparing the treatment effect of carotid stenosis in 
older studies, the results of these studies must be interpreted 
with caution because in recent decades not only pharmacol-
ogical management of cerebrovascular disease but also the 
technical equipment and skills of revascularisation have been 
improved [42]. 
In 1997, Alexopoulus et al. [49] suggested the "vascular 
depression" hypothesis, which is supported by the comorbid-
ity of depression, vascular disease and vascular risk factors 
and by the association of ischaemic lesions to distinctive 
behavioural symptoms. A recent update of the vascular de-
pression hypothesis confirmed that vascular depression can 
be regarded as a distinct subtype of late life depression char-
acterised by specific clinical presentation and association 
with vascular risk factors and a variety of cerebrovascular 
lesions, as shown by structural magnetic resonance imaging 
(MRI). The mechanisms how vascular disease may influence 
the development and course of depression are mechanistic 
disconnection, inflammation and hypoperfusion [9]. There-
fore, one of the aims of our study was to assess the relation-
ship between severe carotid stenosis and depressive symp-
toms. Most patients with severe carotid stenosis also have 
several cardiovascular risk factors (AH, dyslipidaemia, vas-
cular comorbidities, DM), which itself may cause white mat-
ter damage. If the small vessels are already impaired, 
autoregulation of cerebral blood flow is affected as well. 
Therefore, the presence of severe carotid stenosis and im-
paired cerebrovascular reserve reduces the cerebral perfusion 
pressure even more [50]. Development of depression may be 
decreased by revascularisation of carotid stenosis which in-
creases the cerebral perfusion pressure and reduces ischae-
mic lesion due to hypoperfusion. In contrast to Mlekusch  
et al. study where a significant reduction of depressive 
symptoms was found in patients who underwent CAS [51], 
results of our study did not show statistically significant dif-
ferences in the frequencies of depressive symptoms at 6 or 
12 months not only in the BMT group but also in the CEA 
and CAS groups. Therefore, we argue about the direct causal 
relationship between severe carotid stenosis and depression 
and beneficial effects on the course of depressive symptoms 
after revascularisation. Nevertheless, other studies have also 
evaluated change in depressive symptoms using variable 
scales such as Beck Depression and Anxiety Scale [45], 
Hamilton Depression Rating Scale [43-47]. Geriatric De-
pression Scale [52], Hospital Anxiety and Depression Scale 
[42], where no statistically significant differences in mood or 
depressive symptoms over follow up periods or between 
CEA and CAS groups were observed. Therefore, if we sup-
pose that vascular depression may share similar pathogenetic 
mechanisms with cognitive impairment, lack of reversibility 
of depressive symptoms could suggest that depression may 
be a marker for more severe brain structural damage or dys-
function where these changes are no more reversible [53]. 
These irreversible changes could also explain why patients 
with vascular depression have poor response to depression 
treatment [9]. However, this hypothesis is unclear and needs 
further investigations. 
In this study, we found that patients undergoing CEA had 
similar mean values of all SF-36v2 domains at 6 and 12 
months compared to pre-procedure levels. In CAS group 
mean SF-36v2 scores also did not change during the follow-
up period except for BP where the worst scores were after 12 
months. However, in the BMT group measures of RP, BP 
and MCS worsened after 6 and 12 months compared to SF-
36v2 scores at the beginning of the study. So far, literature 
review and meta-analysis have shown that CEA and CAS 
maintain preoperative HRQoL for at least 1 year which is 
partially congruent with our findings [32, 54]. In our study, 
most of the patients in the CEA and CAS groups were as-
ymptomatic, whereas symptomatic patients had TIA or mi-
nor stroke that was not disabling. Therefore, it is reasonable 
not expect superior HRQoL compared to baseline, particu-
larly for previously asymptomatic patients [32]. However, in 
the BMT group, HRQoL worsened. Martin et al. reported 
that patients with TIA or minor stroke in the CEA cohort 
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Therefore, the interpretation of our findings could highlight 
some anxieties over future ischaemic events or doubts of 
treatment choice in patients who refused revascularisation of 
carotid stenosis. As majority of patients had symptomatic ca-
rotid stenosis in the BMT group, probable reason for de-
creased values of RP could be gradual worsening of neuro-
logical deficit due to chronic hypoperfusion of the brain where 
brain plasticity is more restricted; the same could also be re-
ferred to patients with severe asymptomatic carotid stenosis. 
BMT alone cannot reduce the degree of stenosis and improve 
the perfusion of the entire hemisphere, build collateral con-
duits for blood flow or limit the effects of encephalomalacia 
and neuronal loss caused by chronic ischaemia [56].  
Comparing HRQoL between treatment groups during the 
follow-up period, we found that patients undergoing CEA 
had better HRQoL during the 6 and 12 months after carotid 
revascularisation relative to patients undergoing CAS or re-
ceiving BMT only. Six months after CEA, these benefits 
were most pronounced for measures of overall PF, RP and 
PCS. Whereas at 12 months - for PF and SF. Several studies 
have compared HRQoL after CEA versus CAS in patients 
with severe carotid stenosis. Most of these studies report that 
there are no differences between CEA and CAS at 1 year 
with similar HRQoL for CEA and CAS in all domains of SF-
36v2 [57-59]. The comment for this discrepancy with our 
findings could be that in the CAS group we had patients with 
more cardiovascular risk factors as in the CEA group. It is 
known that HRQoL is poorer in patients with cardiovascular 
risk factors compared to other chronic illnesses, where CAD 
imposes one of the greatest decrements across a broad range 
of domains of functioning and perceived HRQoL [60, 61]. In 
addition, in the CAS group during the follow-up, BP wors-
ened, which may have affected scores of the overall PCS. 
Several limitations of this study should be acknowledged. 
First, this was an observational cohort study where patients 
were treated according to preference and consequently selec-
tion has occurred by choosing a treatment modality. The aim 
of our study was to assess changes in cognitive function, 
depressive symptoms and HRQoL after carotid revasculari-
sation and BMT not to compare carotid stenosis treatment 
modalities and their effect on outcomes. Therefore random-
ized controlled trials are needed to confirm our findings as 
well as to evaluate effect of revascularisation on cognitive 
function, depressive symptoms and HRQoL. Second, our 
study had non-uniform sample sizes across study groups and 
was not completely balanced with regard to comorbidities, 
having disproportionate percentage of cardiovascular comor-
bidities in the CAS group and ischaemic events in the BMT 
group. However, to reduce the probability of incorrect results 
of statistical significance due to different sample sizes, we 
calculated effect sizes to quantify the magnitude of the dif-
ference between study groups. Third, the lack of brain imag-
ing may be a cause of incorrect classification of symptomatic 
or asymptomatic carotid stenosis because mild symptoms 
may be unnoticed by the patient. Besides there is a question 
whether new ischaemic lesions on early diffusion weighted 
imaging after revascularisation may affect cognitive function 
because some studies have observed partial reversibility of 
these lesions [62]. Therefore MRI imaging in randomized 
controlled trials after revascularisation could give insight 
whether and how MRI changes or differences affect the re-
sults of cognitive function.  
However, this study to our knowledge has larger BMT 
control group than any previous trials. In addition, we evalu-
ated not only long-term changes in cognition, but also long-
term changes in depressive symptoms and HRQoL in pa-
tients with severe (≥ 70%) carotid stenosis after revasculari-
sation and in the BMT group. Therefore the results and sug-
gestion of our study should be confirmed in further studies.  
CONCLUSION 
Patients with severe carotid stenosis who underwent re-
vascularisation enhanced their cognitive performance with-
out exerting significant change of depressive symptoms. 
Preoperative HRQoL may be maintained for at least one year 
in the CEA group whereas the presence or absence of 
HRQoL change after carotid stenting remains equivocal. 
LIST OF ABBREVIATIONS 
AF = Atrial Fibrillation 
AH = Arterial Hypertension 
ANOVA = Analysis of Variance 
BMT = Best Medical Treatment 
BP = Bodily Pain 
CAD = Coronary Artery Disease 
CAS = Carotid Artery Stenting 
CEA = Carotid Artery Endarterectomy 
CREST-2 trial = Carotid Revascularization and 
Medical Management for Asymp-
tomatic Carotid Stenosis Trial 2 
DM = Diabetes Mellitus 
GH = General Health 
HRQoL = Health Related Quality of Life 
ICH = Intracerebral Hemorrhage 
IQR = Interquartile Range 
MCS = Mental Component Summary 
MH = Mental Health 
MI = Myocardial Infarction 
MoCA = Montreal Cognitive Assessment 
Scale 
MRI = Magnetic Resonance Imaging 
mRS = Modified Rankin Scale 
NASCET = North American Symptomatic Ca-
rotid Artery Endarterectomy Trial 
NYHA = New York Heart Association 
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NIHSS = National Institute of Health Stroke 
Scale 
PAD = Peripheral Artery Disease 
PCS = Physical Component Summary 
PF = Physical Functioning 
PHQ-9 = Patient Health Questionnaire-9 
SD = Standard Deviation 
r = Statistical Coefficient (Statistical 
Effect Size for Wilcoxon Signed 
Rank Test) 
RE = Role Limitations Due to Emotional 
Problems or Role Emotional 
RP = Role Limitations Due to Physical 
Problems or Role-physical 
SF = Social Functioning 
SF-36v2 = Medical Outcome Survey Short 
Form 36 Version 2  
TIA = Transient Ischaemic Attack 
V1 = Baseline Visit 1  
V2 = Visit 2 (after 6 months) 
V3 = Visit 3 (after 12 months) 
VT = Vitality  
η2 = Partial Eta Squared, Statistical Co-
efficient (Statistical Effect Size for 
Kruskal-Wallis and ANOVA Tests). 
ETHICS APPROVAL AND CONSENT TO PARTICI-
PATE 
Ethical permission was granted by the Riga Stradins 
University Ethics Committee, Riga, Lativa. 
HUMAN AND ANIMAL RIGHTS 
No animals were used for studies that are base of this re-
search. All the humans used were in accordance with the 
ethical standards of the committee responsible for human 
experimentation (institutional and national), and with the 
Helsinki Declaration of 1975, as revised in 2013 
(http://ethics.iit.edu/ecodes/node/3931). 
CONSENT FOR PUBLICATION 
Informed consent was obtained from all participants be-
fore revascularisation or initiation of best medical treatment. 
CONFLICT OF INTEREST 





EP, EM, DK, AM participated in the conception and de-
sign of the study. EP coordinated the study. EP and IK par-
ticipated in data collection. ER performed the analyses. EP 
wrote the first draft of the manuscript. All authors partici-
pated in the writing and revision of the successive drafts of 
the manuscript. All authors have read and approved the final 
manuscript.  
ACKNOWLEDGEMENTS 
The authors wish to thank Dr. Tatjana Muravska for her 
substantial contribution in data collection. 
REFERENCES 
[1] Naylor AR. Why is the management of asymptomatic carotid 
disease so controversial? Surgeon 2015; 13(1): 34-43. 
[2] Sun J-H, Tan L, Yu J-T. Post-stroke cognitive impairment: 
Epidemiology, mechanisms and management. Ann Transl Med 
2014; 2(8): 80. 
[3] Hackett ML, Pickles K. Part I: Frequency of depression after 
stroke: An updated systematic review and meta-analysis of 
observational studies. Int J Stroke 2014; 9(8): 1017-25. 
[4] Wang T, Mei B, Zhang J. Atherosclerotic carotid stenosis and 
cognitive function. Clin Neurol Neurosurg 2016; 146: 64-70. 
[5] Lal BK, Dux MC, Sikdar S, et al. Asymptomatic carotid stenosis is 
associated with cognitive impairment. J Vasc Surg 2017; 66(4): 
1083-1092. 
[6] Paraskevas KI, Lazaridis C, Andrews CM, et al. Comparison of 
cognitive function after carotid artery stenting versus carotid 
endarterectomy. Eur J Vasc Endovasc Surg 2014; 47(3): 221-31. 
[7] Naylor AR, Ricco JB, de Borst GJ, et al. Management of 
atherosclerotic carotid and vertebral artery disease: 2017 clinical 
practice guidelines of the European Society for Vascular Surgery 
(ESVS). Eur J Vasc Endovasc Surg 2018; 55(1): 3-81. 
[8] Mott M, Koroshetz W, Wright CB. CREST-2: Identifying the best 
method of stroke prevention for carotid artery stenosis: National 
Institute of Neurological Disorders and Stroke Organizational 
Update. Stroke 2017; 48(5): e130-1.  
[9] Aizenstein HJ, Baskys A, Boldrini M, et al. Vascular depression 
consensus report – a critical update. BMC Med 2016; 14(1): 161. 
[10] De Smedt D, Clays E, De Bacquer D. Measuring health-related 
quality of life in cardiac patients. Eur Hear J 2016; 2(3): 149-50.  
[11] North American Symptomatic Carotid Endarterectomy Trial 
Collaborators1, Barnett HJM, Taylor DW, Haynes RB, Sackett DL, 
Peerless SJ, Ferguson GG, Fox AJ, Rankin RN, Hachinski VC, 
Wiebers DO, Eliasziw M. Beneficial effect of carotid endarter-
ectomy in simptomatic patients with high-grade carotid stenosis. N 
Engl J Med 1991; 325(7): 445-53.  
[12] Fischer U, Baumgartner A, Arnold M, et al. What is a minor 
stroke? Stroke 2010; 41(4): 661-6.  
[13] Warlow C. MRC European carotid surgery trial: Interim results for 
symptomatic patients with severe (70-99%) or with mild (0-29%) 
carotid stenosis. Lancet 1991; 337(8752): 1235-43.  
[14] Halliday AW, Thomas D, Mansfiel A. The Asymptomatic Carotid 
Surgery Trial (ACST) rationale and design. Eur J Vasc Surg 1994; 
8(6): 703-10.  
[15] Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/ 
AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SV
S guideline on the management of patients with extracranial carotid 
and vertebral artery disease: A report of the American College of 
Cardiology Foundation/American Heart Association Task F. 
Circulation 2011; 124(4): e54-130. 
[16] Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the 
prevention of stroke in patients with stroke and transient ischemic 
attack: A guideline for healthcare professionals from the American 
Changes in Cognition, Depression and Quality of Life Current Neurovascular Research, 2019, Vol. 16, No. 1    61 
Heart Association/American Stroke Association. Stroke 2014; 
45(7): 2160-2236.  
[17] Nasreddine Ziad. MoCA Instruction Latvian. Available from: http: 
//www.mocatest.org/wp-content/uploads/2015/tests-
instructions/MoCA-Instruction-Latvian.pdf. Accessed 25 Feb 2015. 
[18] Nasreddine Z, Phillips N, Bédirian V, et al. The Montreal 
Cognitive Assessment, MoCA: A brief screening tool for mild 
cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695-9. 
[19] Pendlebury ST, Mariz J, Bull L, et al. MoCA, ACE-R, and MMSE 
versus the national institute of neurological disorders and stroke-
canadian stroke network vascular cognitive impairment 
harmonization standards neuropsychological battery after TIA and 
stroke. Stroke 2012; 43(2): 464-9.  
[20] Bocti C, Legault V, Leblanc N, et al. Vascular cognitive 
impairment: most useful subtests of the Montreal Cognitive 
Assessment in minor stroke and transient ischemic attack. Dement 
Geriatr Cogn Disord 2013; 36(3-4): 154-62. 
[21] Koski L. Validity and applications of the montreal cognitive 
assessment for the assessment of vascular cognitive impairment. 
Cerebrovasc Dis 2013; 36(1): 6-18.  
[22] Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a 
brief depression severity measure. J Gen Intern Med 2001; 16(9): 
606-13.  
[23] Kroenke K, Spitzer RL, Williams JBW, Löwe B. The patient health 
questionnaire somatic, anxiety, and depressive symptom scales: A 
systematic review. Gen Hosp Psychiatry 2010; 32(4): 345-59. 
[24] Kung S, Alarcon RD, Williams MD, et al. Comparing the Beck 
Depression Inventory-II (BDI-II) and Patient Health Questionnaire 
(PHQ-9) depression measures in an integrated mood disorders 
practice. J Affect Disord 2013; 145(3): 341-3. 
[25] Beutel ME, Wiltink J, Kirschner Y, et al. History of depression but 
not current depression is associated with signs of atherosclerosis: 
data from the Gutenberg Health Study. Psychol Med 2014; 44(05): 
919-25. 
[26] Williams LS, Brizendine EJ, Plue L, et al. Performance of the 
PHQ-9 as a screening tool for depression after stroke. Stroke 2005; 
36(3): 635-8.  
[27] De Man-Van Ginkel JM, Hafsteinsdottir T, et al. An efficient way 
to detect poststroke depression by subsequent administration of a 9-
item and a 2-item patient health questionnaire. Stroke 2012; 43(3): 
854-6.  
[28] Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic 
and severity measure. Psychiatr Ann 2002; 32(9): 509-15. 
[29] Vrublevska J, Trapencieris M, Rancans E. Adaptation and 
validation of the Patient Health Questionnaire-9 to evaluate major 
depression in a primary care sample in Latvia. Nord J Psychiatry 
2018; 72(2): 112-8. 
[30] Optum. SF-36 Health Survey Latvian and Russian version- 
Optum.com. 2015 [cited 2015 Mar 3]. Available from: https: 
//campaign.optum.com/optum-outcomes/what-we-do/health-
surveys/sf-36v2-health-survey.html 
[31] Ware JE. Deciding Which Short Form Survey to Use. Features of 
the Short Form Surveys. An excerpt from the user’s manual for the 
SF-36v2 health survey. 2nd ed. 2007 . 
[32] Shan L, Shan J, Saxena A, Robinson D. Quality of life and 
functional status after carotid revascularisation: A systematic 
review and meta-analysis. Eur J Vasc Endovasc Surg 2015; 49(6): 
634-45. 
[33] De Rango P, Caso V, Leys D, et al. The role of carotid artery 
stenting and carotid endarterectomy in cognitive performance: A 
systematic review. Stroke 2008; 39(11): 3116-27.  
[34] Prins ND, Scheltens P. White matter hyperintensities, cognitive 
impairment and dementia: An update. Nat Rev Neurol 2015; 11(3): 
157-65. 
[35] Plessers M, Van Herzeele I, Hemelsoet D, et al. Prospective 
comparison of cognitive effects of carotid endarterectomy versus 
carotid stenting with flow reversal or distal filters. J Clin Exp 
Neuropsychol 2015; 37(8): 834-41.  
[36] Baumgart M, Snyder HM, Carrillo MC, et al. Summary of the 
evidence on modifiable risk factors for cognitive decline and 
dementia: A population-based perspective. Alzheimer’s Dement 
2015; 11(6): 718-26. 
[37] Watanabe J, Ogata T, Higashi T, Inoue T. Cognitive Change 1 
Year after CEA or CAS compared with medication. J Stroke 
Cerebrovasc Dis 2017; 26(6): 1297-305. 
[38] Alosco ML, Gunstad J, Jerskey BA, et al. The adverse effects of 
reduced cerebral perfusion on cognition and brain structure in older 
adults with cardiovascular disease. Brain Behav 2013; 3(6): 626-
36.  
[39] Ghogawala Z, Amin-Hanjani S, Curran J, et al. The effect of 
carotid endarterectomy on cerebral blood flow and cognitive 
function. J Stroke Cerebrovasc Dis 2013; 22(7): 1029-37. 
[40] Baracchini C, Mazzalai F, Gruppo M, et al. Carotid endarterectomy 
protects elderly patients from cognitive decline: A prospective 
study. Surgery 2012; 151(1): 99-106. 
[41] Yan Y, Yuan Y, Liang L, et al. Influence of carotid artery stenting 
on cognition of elderly patients with severe stenosis of the internal 
carotid artery. Med Sci Monit 2014; 20: 1461-8.  
[42] Wapp M, Everts R, Burren Y, et al. Cognitive improvement in 
patients with carotid stenosis is independent of treatment type. 
Swiss Med Wkly 2015; 145: 1-7.  
[43] Carta MG, Lecca ME, Saba L, et al. Patients with carotid 
atherosclerosis who underwent or did not undergo carotid 
endarterectomy: outcome on mood, cognition and quality of life. 
BMC Psychiatry 2015; 15: 277. 
[44] Dempsey RJ, Jackson DC, Wilbrand SM, et al. The preservation of 
cognition 1 yr after carotid endarterectomy in patients with prior 
cognitive decline. Neurosurgery 2018; 82(3): 322-8. 
[45] Kim JJ, Schwartz S, Wen J, et al. Comparison of neurocognitive 
outcomes after carotid endarterectomy and carotid artery stenting. 
Am Surg 2015; 81(10): 1010-4.  
[46] Kougias P, Collins R, Pastorek N, et al. Comparison of domain-
specific cognitive function after carotid endarterectomy and 
stenting. J Vasc Surg 2015; 62(2): 355-62. 
[47] Aleksic M, Huff W, Hoppmann B, et al. Cognitive function 
remains unchanged after endarterectomy of unilateral internal 
carotid artery stenosis under local anaesthesia. Eur J Vasc 
Endovasc Surg 2006; 31(6): 616-21.  
[48] Altinbas A, Van Zandvoort MJE, Van Den Berg E, et al. Cognition 
after carotid endarterectomy or stenting: A randomized 
comparison. Neurology 2011; 77(11): 1084-90.  
[49] Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular 
depression” hypothesis. Arch Gen Psychiatry 1997; 54(10): 915-
22. 
[50] Gupta A, Chazen JL, Hartman M, et al. Cerebrovascular reserve 
and stroke risk in patients with carotid stenosis or occlusion: A 
systematic review and meta-analysis. Stroke 2012; 43(11): 2884-
91.  
[51] Mlekusch W, Mlekusch I, Minar E, et al. Is there improvement of 
“vascular depression” after carotid artery stent placement? 
Radiology 2006; 240(2): 508-14. 
[52] Feliziani FT, Polidori MC, De Rango P, et al. Cognitive 
performance in elderly patients undergoing carotid endarterectomy 
or carotid artery stenting: A twelve-month follow-up study. 
Cerebrovasc Dis 2010; 30(3): 244-51.  
[53] Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and 
cardiovascular disease: A clinical review. Eur Heart J 2014; 35(21): 
1365-72.  
[54] Chabowski M, Grzebien A, Ziomek A, et al. Quality of life after 
carotid endarterectomy: A review of the literature. Acta Neurol 
Belg 2017; 117(4): 829-35. 
[55] Martin P, Fotopoulou M, Baker G, Humphrey P. Health-related 
quality of life after transient ischemic attack and minor stroke: is 
medical or surgical treatment influential? J Stroke Cerebrovasc Dis 
1998; 7(1): 70-5.  
[56] Bauer AM, Bain MD, Rasmussen PA. Chronic cerebral ischemia: 
where “evidence-based medicine” fails patients. World Neurosurg 
2015; 84(3): 714-8. 
[57] CaRESS Steering Committee. Carotid Revascularization Using 
Endarterectomy or Stenting Systems (CaRESS) phase I clinical 
trial: 1-Year results. J Vasc Surg 2005; 42(2): 213-9.  
62    Current Neurovascular Research, 2019, Vol. 16, No. 1 Pucite et al.  
[58] Stolker JM, Mahoney EM, Safley DM, et al. Health-related quality 
of life following carotid stenting versus endarterectomy: Results 
from the SAPPHIRE (Stenting and Angioplasty with Protection in 
Patients at HIgh Risk for Endarterectomy) trial. JACC Cardiovasc 
Interv 2010; 3(5): 515-23. 
[59] Cohen DJ, Stolker JM, Wang K, et al. Health-related quality of life 
after carotid stenting versus carotid endarterectomy: Results from 
CREST (Carotid Revascularization Endarterectomy versus Stenting 
Trial). J Am Coll Cardiol 2011; 58(15): 1557-65. 
[60] Swenson JR. Quality of life in patients with coronary artery disease 
and the impact of depression. Curr Psychiatry Rep 2004; 6(6): 438-
45. 
[61] Martinelli LMB, Mizutani BM, Mutti A, et al. Quality of life and 
its association with cardiovascular risk factors in a community 
health care program population. Clinics 2008; 63(6): 783-8. 
[62] Grunwald IQ, Papanagiotou P, Reith W, et al. Influence of carotid 
artery stenting on cognitive function. Neuroradiology 2010; 52: 61-
6.
 
 
 
 
 
 
 
 
 
 
